Zorifertinib

Generic Name: Zorifertinib

Brand Names: 泽瑞尼

Drug Type: -

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Associated Conditions: -

Associated Therapies: -

Clinical Trials

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases

Phase 2

Completed

Conditions: EGFR Gene Mutation
Non-small Cell Lung Cancer
Brain Metastases

Interventions: Drug: AZD3759
Drug: Erlotinib
Drug: Gefitinib

First Posted Date: 2018-08-31

Last Posted Date: 2024-10-15

Lead Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd.

Target Recruit Count: 492

Registration Number: NCT03653546

Locations: 🇨🇳
China site, Tianjin, China
🇨🇳
China site 0123, Jinan, Shandong, China
🇰🇷
Korea Site, Seoul, Korea, Republic of

and more 3 locations

Phase II Umbrella Study Directed by Next Generation Sequencing

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Avitinib Maleate
Drug: Afatinib
Drug: Pyrotinib Maleate
Drug: Pirotinib
Drug: Nimotuzumab
Drug: Sintilimab
Drug: Crizotinib
Drug: X-396
Drug: AZD3759
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cisplatin
Drug: Chidamide
Drug: Carboplatin

First Posted Date: 2018-07-02

Last Posted Date: 2022-12-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 400

Registration Number: NCT03574402

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: AZD3759

First Posted Date: 2017-12-04

Last Posted Date: 2022-11-25

Lead Sponsor: LYZZ Alpha Holding Ltd

Target Recruit Count: 15

Registration Number: NCT03360929

Locations: 🇨🇳
0004, Wuhan, Hubei, China
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳
0003, Hangzhou, Zhejiang, China

and more 1 locations

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Interventions: Drug: AZD3759
Drug: AZD9291

First Posted Date: 2014-08-29

Last Posted Date: 2021-01-05

Lead Sponsor: AstraZeneca

Target Recruit Count: 108

Registration Number: NCT02228369

Locations: 🇨🇳
Research Site, Taipei, Taiwan

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy